Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Lineage	$ (18,609,000)	$ (21,486,000)
Net loss attributable to noncontrolling interest	27,000	7,000
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:
Issuance costs for common stock warrant liabilities	688,000	0
Loss on marketable equity securities, net	8,000	176,000
Accretion of income on marketable debt securities	(229,000)	(679,000)
Depreciation and amortization expense	587,000	562,000
Change in right-of-use assets and liabilities	(42,000)	91,000
Amortization of intangible assets	22,000	130,000
Stock-based compensation	5,077,000	4,640,000
Change in fair value of warrant liability	(2,128,000)	0
Deferred income tax benefit	0	(1,803,000)
Foreign currency remeasurement and other loss	273,000	600,000
Changes in operating assets and liabilities:
Accounts receivable	106,000	(446,000)
Prepaid expenses and other current assets	489,000	(418,000)
Accounts payable and accrued liabilities	(1,681,000)	(2,295,000)
Deferred revenue	(7,680,000)	(7,645,000)
Net cash used in operating activities	(23,092,000)	(28,566,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of marketable equity securities	18,000	196,000
Purchases of marketable debt securities	(8,761,000)	(16,403,000)
Maturities of marketable debt securities	7,000,000	63,330,000
Purchase of equipment	(565,000)	(674,000)
Net cash (used in) provided by investing activities	(2,308,000)	46,449,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from employee options exercised	229,000	88,000
Common shares received and retired for employee taxes paid	(23,000)	(37,000)
Payment of financed insurance premium	(171,000)	0
Repayment of finance lease liabilities	(54,000)	(54,000)
Net cash provided by financing activities	35,857,000	6,423,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(95,000)	(250,000)
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	10,362,000	24,056,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period	35,992,000	11,936,000
At end of the period	46,354,000	35,992,000
SUPPLEMENTAL DISCLOSURES
Cash paid for interest	9,000	10,000
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTINGACTIVITIES:
Financing costs in accounts payable and accrued liabilities	179,000	0
Fair value of warrant liability recognized upon issuance in registered direct financing	8,289,000	0
Financed insurance premium	855,000	0
Reconciliation of cash, cash equivalents and restricted cash, end of period:
Cash and cash equivalents	45,789,000	35,442,000
Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))	565,000	550,000
Total cash, cash equivalents, and restricted cash	46,354,000	35,992,000
ATM [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares, net of offering costs	68,000	6,426,000
Direct Financing [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares, net of offering costs	13,889,000	0
Warrants Under Registered Direct Financing [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares, net of offering costs	$ 21,919,000	$ 0